HCA Healthcare filings document a NYSE-listed healthcare services company whose common stock is registered under Section 12(b) and whose wholly owned subsidiary, HCA Inc., issues senior unsecured notes guaranteed by the parent. Recent 8-K reports record quarterly operating results, dividends, share repurchase authorization, commercial paper and debt refinancing activity, and indenture supplements for senior notes.
Proxy and annual-meeting disclosures cover director elections, shareholder voting results, board matters, executive compensation, and performance award programs linked to EBITDA and quality measures. Registration and offering-related filings describe shelf registration use, prospectus supplements, note terms, guarantees, trustee arrangements and capital-structure disclosures for HCA's healthcare services operations.
HCA Healthcare, Inc. reported the results of its Annual Meeting of Stockholders held on April 23, 2026. A total of 209,777,472 shares of common stock were represented in person or by proxy out of 223,568,966 shares outstanding and entitled to vote as of the record date.
Stockholders elected nine directors to one-year terms, with each nominee receiving more votes "For" than "Against." They also ratified the appointment of Ernst & Young LLP as independent registered public accounting firm for the year ending December 31, 2026.
Stockholders approved a non-binding advisory resolution on named executive officer compensation, and two stockholder proposals—one requesting a report on healthcare consequences and another on shareholders’ right to act by written consent—did not receive sufficient support for approval.
HCA Healthcare, Inc. announced that its wholly owned subsidiary, HCA Inc., plans a public offering of senior unsecured notes, with final terms such as maturity, interest rate and principal amount to be set at pricing. The notes will be issued under an effective shelf registration.
HCA Inc. has given notice to redeem all $1.500 billion of its 5.250% senior notes due June 2026 and all $1.000 billion of its 5.375% senior notes due September 2026 on May 27, 2026, subject to receiving net proceeds from the new offering. HCA Inc. intends to use net proceeds for general corporate purposes, which may include repaying borrowings under its $4.000 billion commercial paper program and redeeming some or all of these 2026 notes.
HCA Inc. is offering multiple series of senior notes, each to be fully and unconditionally guaranteed on a senior unsecured basis by parent HCA Healthcare, Inc. The prospectus supplement states interest will be paid semi‑annually and the notes may be redeemed optionally; a Change of Control Triggering Event would permit holders to require repurchase at 101% plus accrued interest. Net proceeds are intended for general corporate purposes and may be used to repay commercial paper and to redeem some or all of the $1.500 billion 5.250% notes due June 2026 and the $1.000 billion 5.375% notes due September 2026. The document also discloses first quarter 2026 operating results: revenues of $19.109 billion, net income attributable to HCA Healthcare, Inc. of $1.620 billion and Adjusted EBITDA of $3.802 billion.
HCA Healthcare, Inc. filed a shelf registration statement on Form S-3 to register offerings of common stock, preferred stock and debt securities and to permit resale of common stock by one or more selling stockholders "from time to time after the effective date of this registration statement."
The prospectus covers general terms for these securities and states the last reported NYSE sale price for HCA common stock was $432.46 per share on April 24, 2026. Specific offering amounts, prices and other terms will be provided in prospectus supplements.
HCA Healthcare, Inc. reported first quarter 2026 results showing modest growth and solid cash generation. Revenues rose 4.3% to $19.109 billion, while net income attributable to HCA increased 0.6% to $1.620 billion. Diluted earnings per share climbed 10.9% to $7.15, helped by share repurchases.
Adjusted EBITDA grew 1.9% to $3.802 billion, and cash flows from operating activities increased 22.0% to $2.014 billion. Management noted weaker seasonal respiratory volumes and weather-related impacts, largely offset by certain Medicaid supplemental program recognition.
The company continued significant capital deployment, with $1.119 billion in capital expenditures and repurchase of 3.157 million shares for $1.571 billion. The board declared a quarterly dividend of $0.78 per share, payable June 30, 2026. HCA reaffirmed its full-year 2026 guidance, including projected revenues of $76.5–$80.0 billion and Adjusted EBITDA of $15.55–$16.45 billion.
The Vanguard Group filed an Amendment No. 8 to Schedule 13G/A reporting zero beneficial ownership of HCA Healthcare Inc. common stock. The filing states Vanguard completed an internal realignment on January 12, 2026 and certain subsidiaries will report beneficial ownership separately in reliance on SEC Release No. 34-39538. The filing lists 0 shares and 0% ownership and includes a signed certification by Ashley Grim, Head of Global Fund Administration.
HCA Healthcare, Inc. is holding its 2026 annual meeting of stockholders as a virtual-only webcast on April 23, 2026 at 2:00 p.m. CDT. Stockholders of record at the close of business on February 23, 2026, when 223,568,966 common shares were outstanding, may vote.
Items up for vote include electing directors, ratifying Ernst & Young LLP as independent auditor for 2026, an advisory say‑on‑pay resolution, and two stockholder proposals on a report about healthcare consequences and on shareholders’ right to act by written consent.
The proxy also details HCA’s governance structure, committee composition, and extensive corporate responsibility efforts, including operating 190 hospitals and numerous outpatient facilities, handling about 47 million patient encounters in 2025, providing an estimated $4.5 billion of uncompensated care, and paying approximately $33 billion in payroll and benefits to about 320,000 colleagues.
HCA Healthcare, Inc. adopted a 2026 Executive Officer Performance Excellence Program that pays cash performance awards to executive officers based on financial and quality results. Awards are weighted 80% on EBITDA targets and 20% on quality metrics covering infections and sepsis, complications and mortality, and care experience.
For EBITDA, payouts range from 25% of the EBITDA portion at threshold performance to 200% at maximum performance, with 100% at target. For each quality metric, payouts range from 0% at or below threshold to 200% at maximum, but no quality payout is made if actual EBITDA is less than 90% of the EBITDA target. The Compensation Committee may adjust metrics and results for unusual events, and awards are subject to discretionary and mandatory clawbacks, including in the case of restated results or specified misconduct. HCA also disclosed that director Robert J. Dennis will not stand for re-election and will retire from the Board at the April 23, 2026 annual meeting.
HCA Healthcare EVP & Chief Legal & Admin Officer Michael R. McAlevey reported a mix of equity transactions involving company stock. On February 13, 2026, he exercised 5,000 Stock Appreciation Rights, receiving 5,000 shares of Common Stock at an exercise price of $236.61 per share. To cover associated tax obligations, 3,306 shares of Common Stock were disposed of at $540.29 per share through a tax-withholding transaction, rather than an open-market sale. On February 18, 2026, he completed an open-market sale of 1,694 shares of Common Stock at an average price of $533.3747 per share, leaving him with 8,853 shares of directly owned Common Stock afterward. The filing also notes indirect holdings of 2,111 shares held by a 2024 GRAT and 26 shares held in a fully managed account; for the managed account, he has no investment authority and disclaims beneficial ownership except to the extent of any pecuniary interest.